Jan 16 (Reuters) - Celgene Corp is in talks to buy Juno Therapeutics Inc, the Wall Street Journal reported, citing sources familiar with the matter. ( on.wsj.com/2EMlysO )
Shares of Juno, which has a market value of $5.57 billion, were up 36 percent at $62.50 in extended trading on Tuesday.
The WSJ report comes days after Celgene said it had agreed to acquire Impact Biomedicines for as much as $7 billion, subject to certain milestones associated with regulatory hurdles and sales performance. (Reporting by Ankur Banerjee in Bengaluru)
 